Desirial

Product Summary

Desirial is a cross-linked hyaluronic acid dermal filler product that has been developed specifically for treating female vulvo-vaginal conditions, such as vaginal atrophy.

Desirial Products logo

Treatment with Desirial is also marketed as ‘labial puff’ or as a non-surgical labiaplasty, whereby injectables are being used to add volume to the labia majora.

Introduced to the UK in January 2014, it is manufactured and distributed by the French company, Laboratoires VIVACY. This is the same company behind the Stylage range of dermal fillers used for facial rejuvenation and volumisation.


Generic name

Cross-linked, non-animal hyaluronic acid (NaHa) with mannitol.


What does it contain?

Desirial contains cross-linked hyaluronic acid which is made using IPN-like® Technology (Interpenetrated Network), Vivacy has created something which has two structures—the monophasic A and B structure, and the IPN-like structure. The two are mechanically independent, so Desirial is easy to inject and the increased density of its cross-linking nodes make it long-lasting. This method requires less BDDE (a common compound used in cross linking hyaluronic acids) which the company claims is more effective and results in a safer, longer lasting product.

Desirial has also been combined with an antioxidant, mannitol, which is naturally present in nature in celery, olives and raspberries and is used to reduce the side effects of injecting hyaluronic acid, namely, redness and swelling. When a needle is inserted into the skin, it triggers a free radical reaction, which can cause a deleterious reaction within the hyaluronic gel. The presence of mannitol, the "free radical scavenger", limits the effects of free radicals on the product injected, thus reducing the risk of post-injection inflammation and preventing the hyaluronic acid gels structure degradation by the body quite so quickly, so that it lasts longer.


How is it made?

Desirial is manufactured using the fermentation of certain bacteria. Mannitol is a naturally occurring antioxidant which contributes to the hydration of the treated tissues.


What is it used to treat?

As women age, like many other parts of the body, the vaginal labia majora (the outermost folds or lips surrounding the vagina) lose their youthfulness and can become lax and somewhat deflated due to tissue volume loss. Changes in this region can be compounded with childbirth and the menopause, leading to both cosmetic and functional concerns for the woman.

According to Laboratoires Vivacy, as many as 80% of women entering menopause are affected by vaginal dryness and about 50% of women completing menopause continue to experience vaginal dryness.

During menopause, there is a decrease of estrogen secretion, which has an effect on fibroblasts, the building blocks of new skin cells and this leads to a progressive loss of elasticity and plumpness in the area of the labia majora. The vaginal mucosa, the redder skin area which is normally protected by the labia majora, becomes dry; the connective tissue has less blood flow to it, is less hydrated and becomes thinner. The glandular cells get less nutrition which makes them waste away and begin to function poorly. As a result, skin dryness, loss of elasticity, flaccidity and fragility appear in the vaginal region.

Desirial can be used to rejuvenate the labia majora, conceal the labia minora for a more symmetrical and proportional appearance and improve dryness.

Generally treatment is performed in conjunction with application of a topical local anaesthetic cream to avoid discomfort.


Is a skin test required before treatment?

No allergy test needed.


Is it temporary or permanent?

Hyaluronic acid is completely broken down within the skin over a period of months, eventually leaving no trace of the filler. Desirial treatment typically lasts for approximately 1-2 years.


Licenced status

Class III medical device, CE mark 0499.


Should be used by

Trained members of the medical profession only, including gynaecologists, doctors, plastic surgeons and specialist nurses who have undertaken specific training.


Product range

There are two different formulations for Desirial available which include:

 

The range of desirial products

Desirial

(2x1ml syringes, 2x1/2” 27g needles + 2x1/2” 30g needles, IPN-like cross-linked NaHa 19mg/ml)  

Suitable for peri-menopausal women or those of reproductive age who are suffering from dehydration of the vulva, with or without irritation.

Desirial is used to treat trophic conditions, restoring hydration, tone, elasticity and sensitivity, while reducing mucosal dryness and strengthening the delicate muscles within the vagina, restoring suppleness. Typical conditions that can be treated using Desirial include: dyspareunia, dryness, vulvodynia, irritation, discomfort, itching and heat/pulling sensations in peri-menopausal individuals.

Desirial Plus

(1x2ml syringe, 2x1/2” 27g needles + 1x18g cannula, IPN-like cross-linked NaHa 21mg/ml)

Suitable for peri-menopausal, menopausal and those of reproductive age with a predisposition for or manifest signs of moderate to severe hypotrophy or atrophy of the labia majora.

Desirial Plus is a cohesive gel, used to treat imperfections of the vulva, as well as functional disorders including vaginal atrophy and moderate to severe symptoms of lipoatrophy (fat loss) of the labia majora.


Not to be used in

There are no specific contraindications for treatment. Generally, all women will be suitable for treatment with Desirial and Desirial Plus, although your doctor or treatment provider should be able to provide you with more information about whether or not this treatment is suitable for you.


Duration of effect

Treatment lasts for at least six months, but usually for approximately one to two years. Results are usually visible immediately.


Reported side effects

Transient erythema (redness), swelling, pain, itching, discolouration or tenderness at the treatment site.


Costs

This depends on the area treated and how much is required, and the practitioner doing the treatment, but price ranges are in the region of £150 per syringe.